EU Competition Council tackles fake products

5 October 2008

The European Commission has welcomed a resolution from the European Union's Competitiveness Council for more effective ways of combating counterfeiting and copyright piracy. The Internal Market Commissioner, Charlie McCreevy, said: "we have to stamp out counterfeiting. It is harming our innovative industries, our economic growth and job creation." He added that "former cocaine and other illegal drug dealing gangs are now turning to peddling counterfeit pharmaceuticals because there is quicker, easier money to be made and more of it. These people do not care about society or about the health and safety of our citizens."

The Council recommended a number of actions to be taken by the Commission, such as the establishment of a counterfeiting and piracy observatory to enable "a regular assessment to be made, on the basis of the data which the public and private sectors wish to provide, of the extent of counterfeiting and piracy and a more precise analysis of these phenomena." Other proposals include an on-line information campaign on the issue, a European awareness day, and specific ideas for the rapid transfer of information about such activities across EU institutions and member states.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight